欢迎访问ProbeChem中文网站,英文网站请访问www.probechem.com

首页-抗体和重组蛋白-Biosimilar Antibody-Camrelizumab
Camrelizumab

Chemical Structure : Camrelizumab

CAS No.: 1798286-48-2

Camrelizumab (Anti-huamn PD1 mAb, human IgG4 (S228P)-Kappa; SHR-1210)

货号: PC-Ab1118Not For Human Use, Lab Use Only.

Camrelizumab (HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death protein 1 (PD-1), binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and p

规格 价格 库存 数量
1 mg ¥3580 In stock
5 mg ¥7580 In stock
10 mg ¥12800 In stock
100 mg Get quote

大包装,大折扣!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

纯度 & COA & 质检文件 纯度: >98% (HPLC) Select Batch:

生物&药学活性

Camrelizumab (HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death protein 1 (PD-1), binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs).

物理化学性质&存储条件

分子量
分子式 Human IgG4 (S228P)-Kappa
外观性状 Solid
CAS No.
储存条件
固体粉末
-20 °C 12 个月; 4°C 6 个月
配置液
-80 °C 6 个月; -20°C 6 个月
Shipping
Solubility

PBS, pH 7.0 Contains no stabilizers or preservatives

Chemical Name/SMILES

Camrelizumab; SHR-1210; SHR1210; HR 301210, INCSHR 1210; 1798286-48-2; Anti-human programmed death receptor-1; Anti-human PD1

参考文献

1. 1, Zhou C, et al. Lancet Respir Med. 2021 Mar;9(3):305-314.  2, Xu J, et al. Clin Cancer Res. 2021 Feb 15;27(4):1003-1011. 3, Lan C, , et al. J Clin Oncol. 2020 Dec 1;38(34):4095-4106. 4, Xu J, et al. Clin Cancer Res. 2019 Jan 15;25(2):515-523.  5, Huang J, et al. Cancer. 2019 Mar 1;125(5):742-749. 

备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

联系我们 sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

询单

  • *产品名称:
  • *姓名:
  • *邮箱:
  • *公司名称:
  • *询单数量:
  • *国籍:
  • 询单信息: